SELLAS Life Sciences Group, Inc.
Congressional Trades
No congressional trades in SLS on record.
Whale Activity
- Increased94
- New43
- Held31
- Decreased36
- Closed22
- No prior filing13
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 16.2M | $199.2M | increased |
| STATE STREET CORP | 10.4M | $127.7M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 8.9M | $110.1M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 5.2M | $63.7M | increased |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.6M | $32.5M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.3M | $28.3M | increased |
| NORTHERN TRUST CORP | 1.9M | $22.8M | increased |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.8M | $22.2M | increased |
| MORGAN STANLEY | 1.5M | $18.6M | increased |
| UBS Group AG | 1.5M | $18.3M | increased |
| VANGUARD FIDUCIARY TRUST CO | 1.4M | $17.7M | increased |
| DAGCO, INC. | 1.3M | $16.5M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Burns John ThomasCFO | Sale | −3,831 | $19.18 | $73K | Nov 18, 2026 | Form 4 ↗ |
| CICIC DRAGANSVP, Chief Development Officer | Sale | −6,933 | $19.18 | $133K | Nov 18, 2026 | Form 4 ↗ |
| Stergiou Angelos M.President and CEO · Director | Sale | −26.6K | $19.18 | $510K | Nov 18, 2026 | Form 4 ↗ |
| Stergiou Angelos M.President and CEO · Director | Grant / award | +1.1M | $0.00 | $0 | Jun 16, 2026 | Form 4 ↗ |
| Varian JohnDirector | Grant / award | +50.0K | $0.00 | $0 | Jan 7, 2026 | Form 4 ↗ |
| VAN NOSTRAND ROBERT LDirector | Grant / award | +50.0K | $0.00 | $0 | Jan 7, 2026 | Form 4 ↗ |
| SCHEINBERG DAVID ADirector | Grant / award | +50.0K | $0.00 | $0 | Jan 7, 2026 | Form 4 ↗ |
| CICIC DRAGANSVP, Chief Development Officer | Grant / award | +300.0K | $0.00 | $0 | Jan 7, 2026 | Form 4 ↗ |
| Burns John ThomasCFO | Grant / award | +300.0K | $0.00 | $0 | Jan 7, 2026 | Form 4 ↗ |
| Kalin Katherine BachDirector | Grant / award | +50.0K | $0.00 | $0 | Jan 7, 2026 | Form 4 ↗ |
| Wasman JaneDirector | Grant / award | +50.0K | $0.00 | $0 | Jan 7, 2026 | Form 4 ↗ |
| CICIC DRAGANSVP, Chief Development Officer | Other | −63.8K | $1.50 | $96K | Dec 3, 2025 | Form 4 ↗ |
| Burns John ThomasCFO | Other | −58.6K | $1.50 | $88K | Dec 3, 2025 | Form 4 ↗ |
| Stergiou Angelos M.President and CEO · Director | Other | −187.1K | $1.50 | $281K | Dec 3, 2025 | Form 4 ↗ |
| Kalin Katherine BachDirector | Purchase | +63.4K | $1.59 | $101K | Nov 19, 2025 | Form 4 ↗ |
| VAN NOSTRAND ROBERT LDirector | Purchase | +10.0K | $1.48 | $15K | Jun 12, 2025 | Form 4 ↗ |
| Wasman JaneDirector | Purchase | +20.0K | $1.69 | $34K | May 30, 2025 | Form 4 ↗ |
| Kalin Katherine BachDirector | Purchase | +20.0K | $1.80 | $36K | May 22, 2025 | Form 4 ↗ |
| Burns John ThomasCFO | Grant / award | +81.3K | $0.00 | $0 | Jan 10, 2025 | Form 4 ↗ |
| Burns John ThomasCFO | Grant / award | +113.0K | $0.00 | $0 | Jan 10, 2025 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 8.7M | $127.7M | 1.19% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.9M | $87.2M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 4.9M | $72.7M | 0.09% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.1M | $31.5M | 0.03% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 1.7M | $25.7M | 0.17% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 2.1M | $20.7M | 0.06% | Jul 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 1.1M | $14.4M | 0.08% | Aug 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 910.7K | $12.1M | 0.03% | Aug 31, 2026 |
| iShares Micro-Cap ETF iShares Trust | 632.2K | $9.3M | 0.61% | Jun 30, 2026 |
| VANGUARD HEALTH CARE INDEX FUND VANGUARD WORLD FUND | 546.8K | $7.3M | 0.03% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list SLS's shares (CUSIP 81642T209), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 10.4M shares5.1%
Nov 10, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 15.9M shares7.9%
Oct 27, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 13.0M shares7.0%
Aug 7, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 9.7M shares5.2%
Jul 31, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming SELLAS Life Sciences Group, Inc. as the client.
Government Contracts
No federal contract awards found for SELLAS Life Sciences Group, Inc..
U.S. Patents
No USPTO patent applications found for SELLAS Life Sciences Group, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | $0 | $1.0M | $7.6M |
| Operating income | -$28.3M | -$31.5M | -$37.9M | -$42.0M | -$25.3M |
| Net income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | -$20.7M |
| Diluted EPS | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 |
| Operating cash flow | -$28.4M | -$35.4M | -$31.4M | -$23.8M | -$26.0M |
| Cash and equivalents | $71.8M | $13.9M | $2.5M | $17.1M | $21.4M |
| Total assets | $78.3M | $19.4M | $6.2M | $20.9M | $26.3M |
| Total liabilities | $7.5M | $10.0M | $14.2M | $16.1M | $5.9M |
| Shareholders' equity | $70.9M | $9.5M | -$8.0M | $4.9M | $20.3M |
As SELLAS Life Sciences Group, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 19, 2026 ↗
Stock Splits
- 1-for-50Reverse splitNov 8, 2019
- 1-for-30Reverse splitJan 2, 2018
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsNov 20, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsNov 17, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 11, 2026
EDGAR ↗ - 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsJul 27, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeJun 25, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 18, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 2, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 12, 2026
EDGAR ↗
